First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Rotow, J. K. [1 ]
Waqar, S. N. [2 ]
Papadopoulos, K. P. [3 ]
Hung, J-Y. [4 ,5 ]
Spira, A. I. [6 ]
Gan, H. [7 ]
Yoshida, T. [8 ]
Kuo, C-H. S. [9 ]
Doger de Speville, B. [10 ]
Felip, E. [11 ]
Yoh, K. [12 ]
Morrison-Thiele, G. [13 ]
Robinson, R. [14 ]
Rudraganguly, N. [14 ]
Saab, R. [15 ]
Cho, B. C. [16 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Washington Univ, Med, Sch Med St Louis, Siteman Canc Ctr, St Louis, MO USA
[3] South Texas Accelerated Res Therapeut START, Dept Clin Res, San Antonio, TX USA
[4] Kaohsiung Med Univ, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan
[5] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Coll Med, Fac Med, Kaohsiung, Taiwan
[6] Virginia Canc Specialists, Dept Med Oncol, US Oncol Res, Fairfax, VA USA
[7] Austin Hlth Austin Hosp, Dept Med Oncol, Heidelberg, Vic, Australia
[8] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[9] Chang Gung Univ, Chang Gung Mem Hosp, Div Thorac Oncol & Intervent Bronchoscopy, Dept Resp Med, Taipei, Taiwan
[10] START Madrid Hosp Univ, Fdn Jimenez Diaz, Madrid, Spain
[11] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[12] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[13] AbbVie Inc, Oncol Early Discovery, Headquarters, N Chicago, IL USA
[14] AbbVie Inc, San Francisco, CA USA
[15] AbbVie Inc, Clin Res, San Francisco, CA USA
[16] Yonsei Univ, Med Oncol Dept 501, ABMRC, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318MO
引用
收藏
页数：1
相关论文
共 48 条
  • [1] A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer
    Hsu, Robert
    Benjamin, David J.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Angevin, Eric
    Strickler, John
    Weekes, Colin
    Heist, Rebecca
    Morgensztern, Daniel
    Fan, Xiaolin
    Olyaie, Ozzie
    Motwani, Monica
    Afar, Daniel
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S395 - S396
  • [3] Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
    Rotow, Julia K.
    Costa, Daniel Botelho
    Paweletz, Cloud P.
    Awad, Mark M.
    Marcoux, Paul
    Rangachari, Deepa
    Barbie, David Allen
    Sands, Jacob
    Cheng, Michael L.
    Johnson, Bruce E.
    Oxnard, Geoffrey R.
    Jackman, David Michael
    Kwiatkowski, David J.
    Kehl, Kenneth L.
    Izdebski, Monika D.
    Lau, Christie J.
    Vasquez, Kevin A.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study
    Eide, I. J.
    Helland, A.
    Borrisova, S.
    Ekman, S.
    Cicenas, S.
    Koivunen, J.
    Gronberg, B. H.
    Brustugun, O. T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2139 - S2140
  • [5] Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study
    Eide, I. J.
    Helland, A.
    Borrisova, S.
    Ekman, S.
    Cicenas, S.
    Koivunen, J.
    Gronberg, B. H.
    Brustugun, O. T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2140 - S2141
  • [6] A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)
    Zhang, L.
    Fang, W. F.
    Zhao, S.
    Yu, Y.
    Yong, T. X.
    Dong, X.
    Zhuang, W.
    Hu, Y.
    Luo, F.
    Wang, Q.
    Chu, Q.
    Fu, Z.
    Yao, Y.
    Ma, X.
    Ding, C.
    Hao, J.
    Yang, X.
    Wan, X.
    Li, M.
    Yang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1624 - S1625
  • [7] Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
    Goldman, J.
    Huang, H. K. T.
    Cummings, A.
    Noor, Z.
    Slomowitz, S.
    Kirimis, E.
    Olevsky, O.
    Arzoo, K.
    Ashouri, S.
    DiCarlo, B.
    Hu, E. H. -L.
    Wong, D. J.
    Chauv, J.
    Garon, E. B.
    Yarden, Y.
    Slamon, D.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S68 - S69
  • [8] IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.
    Chittenden, Thomas D.
    Setiady, Yulius Y.
    Park, Peter U.
    Ponte, Jose F.
    Dong, Ling
    Skaletskaya, Anna
    Carrigan, Christina N.
    Villaluz, Alfred A.
    Pinkas, Jan
    Lutz, Robert J.
    Lambert, John M.
    CANCER RESEARCH, 2013, 73 (08)
  • [9] Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
    Assya Akli
    Nicolas Girard
    Vincent Fallet
    Gaelle Rousseau-Bussac
    Valérie Gounant
    Sylvie Friard
    Jean Trédaniel
    Cécile Dujon
    Marie Wislez
    Boris Duchemann
    Etienne Giroux-Leprieur
    Targeted Oncology, 2022, 17 : 675 - 682
  • [10] Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
    Akli, Assya
    Girard, Nicolas
    Fallet, Vincent
    Rousseau-Bussac, Gaelle
    Gounant, Valerie
    Friard, Sylvie
    Tredaniel, Jean
    Dujon, Cecile
    Wislez, Marie
    Duchemann, Boris
    Giroux-Leprieur, Etienne
    TARGETED ONCOLOGY, 2022, 17 (06) : 675 - 682
12345